These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
28. An update on the use of immunoglobulin for the treatment of immunodeficiency disorders. Albin S; Cunningham-Rundles C Immunotherapy; 2014; 6(10):1113-26. PubMed ID: 25428649 [TBL] [Abstract][Full Text] [Related]
29. Successful treatment of systemic lupus erythematosus with subcutaneous immunoglobulin. Brasileiro A; Fonseca Oliveira J; Pinheiro S; Paiva-Lopes MJ Lupus; 2016 May; 25(6):663-5. PubMed ID: 26846694 [TBL] [Abstract][Full Text] [Related]
30. Home-based subcutaneous immunoglobulin G replacement therapy under real-life conditions in children and adults with antibody deficiency. Hoffmann F; Grimbacher B; Thiel J; Peter HH; Belohradsky BH; Eur J Med Res; 2010 Jun; 15(6):238-45. PubMed ID: 20696632 [TBL] [Abstract][Full Text] [Related]
32. Impact of Site of Care on Infection Rates Among Patients with Primary Immunodeficiency Diseases Receiving Intravenous Immunoglobulin Therapy. Wasserman RL; Ito D; Xiong Y; Ye X; Bonnet P; Li-McLeod J J Clin Immunol; 2017 Feb; 37(2):180-186. PubMed ID: 28160239 [TBL] [Abstract][Full Text] [Related]
37. Use of intravenous immunoglobulin (IVIG) therapy in adults. Herrod HG Allergy Proc; 1994; 15(6):309-12. PubMed ID: 7721079 [TBL] [Abstract][Full Text] [Related]
38. Pharmacokinetics of subcutaneous immunoglobulin and their use in dosing of replacement therapy in patients with primary immunodeficiencies. Berger M; Rojavin M; Kiessling P; Zenker O Clin Immunol; 2011 May; 139(2):133-41. PubMed ID: 21353644 [TBL] [Abstract][Full Text] [Related]
39. [Polyvalent immunoglobins in general pediatrics: what place, what risk, and what cost?]. Dommergues JP; Bader-Meunier B Arch Pediatr; 1999; 6 Suppl 2():397s-399s. PubMed ID: 10370548 [No Abstract] [Full Text] [Related]
40. Subcutaneous immunoglobulin replacement therapy in patients with primary immunodeficiency in routine clinical practice: the VISPO prospective multicenter study. Vultaggio A; Azzari C; Milito C; Finocchi A; Toppino C; Spadaro G; Trizzino A; Baldassarre M; Paganelli R; Moschese V; Soresina A; Matucci A Clin Drug Investig; 2015 Mar; 35(3):179-85. PubMed ID: 25672929 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]